Biostatistics Services for Phase I–IV Clinical Trials

Our Biostatistics services provide comprehensive statistical support across all phases of clinical development, from first‑in‑human studies to post‑marketing research. We support Phase I dose‑escalation and PK/PD analyses, Phase II proof‑of‑concept and endpoint optimization, Phase III confirmatory analyses, and Phase IV real‑world and safety evaluations. Our expertise includes study design, sample size determination, SAP development, interim and final analyses, and regulatory‑grade statistical reporting. Leveraging validated methodologies aligned with FDA, EMA, and ICH standards, we help sponsors and CROs generate robust, interpretable evidence that supports sound decision‑making and successful regulatory submissions.